Gertrude Elion, Nobel Prize winner in Physiology or Medicine (1988), transformed the way we develop drugs.
While her discoveries—drugs for leukemia, herpes, and immunosuppression—were groundbreaking, her greatest contribution was revolutionising the drug development process itself.
Elion, along with George Hitchings and James Black, discarded the traditional trial-and-error approach. Instead, they applied rational, science-driven strategies, targeting the specific biology of disease. By understanding how cells reproduce, they designed drugs to disrupt the lifecycles of rapidly growing bacteria and tumours, creating a blueprint for modern drug design.
Today, innovations like MicroTex carry this legacy forward. MicroTex is reimagining early-stage therapeutic research, using Intra-Target Microdosing (ITM) in Phase 0 studies to test drugs directly at the site of disease. Just as Elion accelerated drug discovery through smarter design, MicroTex accelerates evaluation by generating early, site-specific evidence of effectiveness, potentially reducing costs, timelines, and late-stage failures.
Elion didn’t just discover drugs—she changed the entire system of drug development. MicroTex is building on that spirit of innovation, showing that the future of medicine is smarter, faster, and more precise.